SARS-Cov-2 Infection and Seroconversion Rates in Healthcare Providers Prior to COVID-19 Vaccine Rollout.
SARS-CoV-2
exposure risk
healthcare worker
infection rate
seroconversion rate
Journal
Biological research for nursing
ISSN: 1552-4175
Titre abrégé: Biol Res Nurs
Pays: United States
ID NLM: 9815758
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
14
9
2023
pubmed:
5
3
2023
entrez:
4
3
2023
Statut:
ppublish
Résumé
A 6-month longitudinal surveillance study of asymptomatic healthcare providers (HCP) was carried out at a large urban academic medical center in the United States to assess whether their job occupation with higher exposure risks to SARS-CoV-2 would equate with higher risk of contracting COVID-19 at the beginning of the pandemic before COVID-19 vaccines were available. A longitudinal cohort study design was used to collect and analyze immunological and virological monitoring data and self-report survey assessments of personal protective equipment (PPE) availability, adherence to infection control guidelines, and time spent on COVID-19 wards. Among 289 eligible participants, SARS-CoV-2 exposure risk was high with 48-69% participants working in COVID-19 units and more than 30% of them caring for COVID-19 patients. However, the seroconversion rate was low with only 2.1% of participants developing humoral or cellular immunity against SARS-CoV-2. Our study findings suggest that, for this HCP cohort working at a large urban academic medical center, a low incidence of SARS-CoV-2 infection could be maintained under conditions of strict infection prevention protocols and reliable PPE availability.
Identifiants
pubmed: 36869766
doi: 10.1177/10998004231161632
pmc: PMC9988593
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
505-515Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA028735
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001414
Pays : United States
Références
Curr Protoc Immunol. 2020 Dec;131(1):e116
pubmed: 33215858
Front Microbiol. 2020 Oct 19;11:584251
pubmed: 33193227
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Elife. 2020 Aug 21;9:
pubmed: 32820721
PLoS One. 2020 Nov 12;15(11):e0240006
pubmed: 33180782
Lancet Public Health. 2020 Sep;5(9):e461-e462
pubmed: 32745513
Lancet Infect Dis. 2020 Dec;20(12):1351-1352
pubmed: 32758436
MMWR Morb Mortal Wkly Rep. 2020 Sep 25;69(38):1364-1368
pubmed: 32970661
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
JAMA. 2020 Dec 1;324(21):2155-2156
pubmed: 33185657
Am J Trop Med Hyg. 2021 Jun 17;105(2):395-400
pubmed: 34143752
PLoS One. 2012;7(4):e35797
pubmed: 22563403
Curr Res Immunol. 2022;3:215-221
pubmed: 36065205
Clin Infect Dis. 2021 Jan 27;72(2):301-308
pubmed: 33501951
Lancet. 2021 Mar 20;397(10279):1075-1084
pubmed: 33743869
Syst Rev. 2021 May 26;10(1):155
pubmed: 34039423
Lancet. 2020 Jul 25;396(10246):e6-e7
pubmed: 32653078
Front Mol Biosci. 2021 Jul 23;8:682405
pubmed: 34368226
Lancet Infect Dis. 2020 Oct;20(10):e261-e267
pubmed: 32711692
Infect Control Hosp Epidemiol. 2020 Dec;41(12):1441-1442
pubmed: 32741406
J Med Virol. 2022 Jun;94(6):2343-2345
pubmed: 35098543
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092
pubmed: 34237248
Clin Infect Dis. 2004 Jun 15;38(12):e116-8
pubmed: 15227633